Idoroenyi Amanam, M.D.

800-826-4673
Idoroenyi Amanam, M.D.
Hematologist-Oncologist
Clinical Expertise
  • Leukemia
Research Area
  • Leukemia
  • Stem Cell Transplants
  • Myeloproliferative Neoplasms
Other Languages Spoken
Efik
Ibibio
Academic Appointments
  • Assistant Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Hematology & Hematopoietic Cell Transplantation
Leukemia
Research Teams
Hematologic Malignancies Translational Science
Hematology & Hematopoietic Cell Transplantation

I believe in treating all my patients with compassion and utilizing intellectual curiosity to tailor my treatment approaches.

Idoroenyi Amanam, M.D., is a triple-boarded physician with advanced fellowship training utilizing cellular and stem cell therapy to treat malignant conditions. Dr. Amanam obtained his medical degree from Meharry Medical College in Nashville, Tennessee. He completed his training at St. Mary-UCLA Internal Medicine Residency, where he was awarded Intern of the Year, Resident of the Year and Chief Resident distinctions. Following residency, Dr. Amanam completed his hematology and oncology training here at City of Hope/UCLA-Harbor combined program, serving as chief fellow. He was then awarded the prestigious City of Hope Hematopoietic Cell Transplantation and Cellular Therapy Fellowship, with a concentration on acute leukemias and myeloproliferative neoplasms.

Dr. Amanam is multilingual (English, Ibibio, Efik) and was awarded a U.S. Congressional Award in service — he is motivated to carrying this to the clinic. He firmly believes in serving his patients and enjoys the time spent educating them and their families regarding specifics of their disease.

Dr. Amanam believes he was chosen to enter this field as he had a loved one who struggled with cancer and lived years longer than expected thanks to compassionate care by the doctors and nurses. “That experience always left an impression with me,” he said. “I knew this was the only field for me.”

Dr. Amanam focuses his research on leukemia, stem cell transplants and myeloproliferative neoplasms, when the body produces too many red or white blood cells. “(The) patients are humble,” he explained, “the disease profile is diverse and from a research perspective there is still room for improving outcomes.”

Location

Education & Experience

Board Certifications

  • Basic Life Support Certification
  • Advanced Cardiac Life Support Certification
  • California Medical License
  • Drug Enforcement Agency License
  • Diplomate of the American Board of Internal Medicine
  • 2015, Certification, Internal Medicine
  • 2019, Certification, Medical Oncology
  • 2019, Certification, Hematology

Fellowship

  • 2019-2020, Fellow and Clinical Instructor, City of Hope, Hematopoietic Cell Transplantation and Cellular Therapy, Duarte, CA
  • 2016-2019, Fellow and Chief Fellow, City of Hope/Harbor-UCLA, Hematology/Oncology, Duarte/Los Angeles, CA

Residency

  • 2015-2016, Chief Resident and Clinical Instructor, St. Mary-UCLA Internal Medicine Residency, Long Beach/Los Angeles, CA
  • 2012-2015, Resident, St. Mary-UCLA Internal Medicine Residency, Long Beach/Los Angeles, CA

Professional Experience

  • 2020-Present, Assistant Clinical Professor, Division of Leukemia, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA

Degrees

  • Doctor of Medicine, Meharry Medical College School of Medicine, Nashville, TN

Awards & Memberships

Awards

  • 2019, ASCO Quality Training Program
  • 2018, AACR/ASCO Methods in Clinical Cancer Research Workshop
  • 2017, Clive Davis Research Fellowship Award
  • 2015, Resident of the Year
  • 2015, Conquer Cancer Foundation Resident Travel Award
  • 2014, American College of Physicians
  • 2014, Young Achiever, American College of Physicians
  • 2013, Intern of the Year, Awarded by Department of Medicine with award in Critical Care
  • 2007, Congressional Award, United States Congress, Selected in Category of Voluntary Public Service

Memberships

  • 2016-present, Member, American Society of Hematology
  • 2014-present, Fellow Member, American Society of Clinical Oncology
  • 2011-present, Associate Member, American College of Physicians
  • 2010-present, Member, Physicians for Peace
  • 2004-present, Member, American Medical Association

Publications

  • Tinajero J, Ngo D, Zhang J, Tsai NC, Aribi A, Aldoss I, Agrawal V, Arslan S, Amanam I, Pourhassan H, Sandhu K, Al-Malki M, Pullarkat V, Becker P, Nakamura R, Stein A, Marcucci G, Artz A, Koller P, Salhotra A. High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy. Leuk Lymphoma. 2024 Apr 18:1-4. doi: 10.1080/10428194.2024.2332506. Epub ahead of print. PMID: 38635368.
  • Yao JM, Otoukesh S, Kim H, Yang D, Mokhtari S, Samara Y, Blackmon A, Arslan S, Agrawal V, Pourhassan H, Amanam I, Ball B, Koller P, Salhotra A, Becker P, Curtin P, Artz A, Aldoss I, Ali H, Stewart F, Smith E, Stein A, Marcucci G, Forman SJ, Nakamura R, Al Malki MM. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Transplant Cell Ther. 2023 May 12:S2666-6367(23)01291-5. doi: 10.1016/j.jtct.2023.05.008. Epub ahead of print. PMID: 37182736.
  • Amanam I, Yao J, Puing A, Tsai NC, Samuels D, Ngo D, Ho S, Ali H, Aribi A, Arslan S, Artz A, Htut M, Koller P, Salhotra A, Sandhu K, Nikolaenko L, Pawlowska A, Shouse G, Stein A, Marcucci G, Forman S, Nakamura R, Dadwal S, Al Malki MM. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Cancer Med. 2023 May;12(10):11248-11253. doi: 10.1002/cam4.5832. Epub 2023 Apr 20. PMID: 37081733; PMCID: PMC10242327.
  • Aldoss I, Afkhami M, Yang D, Gu Z, Mokhtari S, Shahani S, Pourhassan H, Agrawal V, Koller P, Arslan S, Tomasian V, Al Malki MM, Artz A, Salhotra A, Ali H, Aribi A, Sandhu KS, Ball B, Otoukesh S, Amanam I, Becker PS, Stewart FM, Curtin P, Smith E, Telatar M, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractor acute lymphoblastic leukemia with Philadelphia-like fusions. Am J Hematol. 2023 Mar 7. doi: 10.1002/ajh.26908. PMID: 36880203
  • Amanam I, Otoukesh S, Al Malki MM, Salhotra A. Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies. Hematology Am Soc Hematol Educ Program. 2023 Dec 8;2023(1):164-170. doi: 10.1182/hematology.2023000427. PMID: 38066845; PMCID: PMC10727045.
  • Agrawal V, Pourhassan H, Tsai NC, Ngo D, Koller P, Malki MMA, Salhotra A, Ali H, Aribi A, Sandhu KS, Arslan S, Ball B, Otoukesh S, Amanam I, Artz A, Singh D, Becker PS, Stewart FM, Smith EP, Curtin P, Stein AS, Marcucci G, Forman SJ, Nakamura R, Pullarkat V, Aldoss I. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Transplant Cell Ther. 2023 May;29(5):314-320. doi: 10.1016/j.jtct.2023.01.017. Epub 2023 Jan 19. PMID: 36682470.
  • La Rosa C, Chiuppesi F, Park Y, Zhou Q, Yang D, Gendzekhadze K, Ly M, Li J, Kaltcheva T, Ortega Francisco S, Gutierrez MA, Ali H, Otoukesh S, Amanam I, Salhotra A, Pullarkat VA, Aldoss I, Rosenzweig M, Aribi AM, Stein AS, Marcucci G, Dadwal SS, Nakamura R, Forman SJ, Al Malki MM, Diamond DJ. Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. Front Immunol. 2023 Mar 3;14:1114131. doi: 10.3389/fimmu.2023.1114131. eCollection 2023.PMID: 36936918
  • Ball BJ, Arslan S, Koller P, Ngo D, Afkhami M, Salhotra A, Al-Malki M, Aribi A, Ali H, Sandhu K, Otoukesh S, Amanam I, Pourhassan H, Artz A, Curtin P, Stein A, Nakamura R, Marcucci G, Smith E, Pullarkat V, Aldoss I. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML). Leuk Lymphoma. 2022 Dec;63(13):3232-3236. doi: 10.1080/10428194.2022.2116934. Epub 2022 Sep 10.PMID: 36089918
  • La Rosa C, Chiuppesi F, Park Y, Gendzekhadze K, Zhou Q, Faircloth K, Kaltcheva T, Johnson D, Ortega Francisco S, Amanam I, Otoukesh S, Pullarkat VA, Nakamura R, Diamond DJ, Forman SJ, Al Malki MM. Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft to hematopoietic stem cell transplant recipients. Am J Hematol. 2022 Nov;97(11):E404-E407. doi: 10.1002/ajh.26691. Epub 2022 Sep 2.PMID: 36053823
  • Amanam I, Ngo D, Pullarkat V, Aldoss I. Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis. Leuk Lymphoma. 2022 Dec;63(13):3268-3270. doi: 10.1080/10428194.2022.2113529. Epub 2022 Aug 25.PMID: 36016465

Ratings & Reviews

Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
5.0
Show respect for what you say
4.9
Recommend this provider office
4.9
Provider explain in way you understand
4.9
Provider listen carefully to you
4.9
Know important info medical history
4.9
Spend enough time with you
4.9
Rate provider 0-10
05/30/25
I had the most pleasant experience with Dr Amanam. Great Dr! - Verified patient
05/23/25
I share City of Hope to everyone that listens to my story - Verified patient
05/23/25
The best facility in the world.. Dr. Amanam and the team is caring and treats us like family - Verified patient
04/30/25
The staff has been taking care of me for over 20 years. I am definitely satisfied with the care here. - Verified patient
04/30/25
This provider goes beyond what I expect. I have 100% confidence in him. - Verified patient